← Back to Search

Diabetes Homeless Medication Support (D-Homes) for Type 2 Diabetes (D-HOMES Trial)

Phase 2
Waitlist Available
Led By Katherine D Vickery, MD, MSc
Research Sponsored by Hennepin Healthcare Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 30 weeks
Awards & highlights

D-HOMES Trial Summary

This trial will compare the effects of a diabetes medication intervention to brief diabetes education on homeless people with diabetes.

Eligible Conditions
  • Type 2 Diabetes
  • Housing Insecurity
  • Psychological Distress

D-HOMES Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 30 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 30 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Experience during the intervention
Retention in assessments
Secondary outcome measures
Change in glycemic control
Diabetes medication adherence
Psychological wellness

D-HOMES Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: D-Homes interventionExperimental Treatment2 Interventions
Behavioral treatments by a diabetes wellness coach as defined below.
Group II: Enhanced usual careActive Control1 Intervention
Brief diabetes educational session by a diabetes wellness coach.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Enhanced usual care
2017
Completed Phase 4
~10570
Diabetes Homeless Medication Support (D-Homes)
2022
Completed Phase 2
~50

Find a Location

Who is running the clinical trial?

Hennepin Healthcare Research InstituteLead Sponsor
90 Previous Clinical Trials
77,139 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,377 Previous Clinical Trials
4,315,773 Total Patients Enrolled
Katherine D Vickery, MD, MScPrincipal InvestigatorHennepin Healthcare Research Institute

Media Library

Diabetes Homeless Medication Support (D-Homes) Clinical Trial Eligibility Overview. Trial Name: NCT05258630 — Phase 2
Type 2 Diabetes Research Study Groups: Enhanced usual care, D-Homes intervention
Type 2 Diabetes Clinical Trial 2023: Diabetes Homeless Medication Support (D-Homes) Highlights & Side Effects. Trial Name: NCT05258630 — Phase 2
Diabetes Homeless Medication Support (D-Homes) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05258630 — Phase 2
~12 spots leftby May 2025